MedTrace Logo

Stanford RAD-AT Study (Research on Anxiety and Depression - Anhedonia Treatment)

NCT02220309 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 167

Last updated 2026-01-05

No results posted yet for this study

Summary

This research study is aimed at understanding behaviors and brain circuits that relate to anxiety and depression. Our goal is to learn which circuits of the brain are involved in anxiety and how these circuits might affect daily functioning.

This study has recently added an additional treatment component: participants undergo a 12 week course of either Pramipexole medication or rTMS therapy (explained below). The ultimate goal of the study is to offer participants experiencing anxiety and depression a treatment that is alternative to ones that have failed them in the past, and to apply the knowledge we gain from investigating the brain circuits involved in anxiety and depression to help personalize treatments.

We invite anyone who has recently experienced any symptoms of anxiety and/or depression to participate (no diagnosis is required to participate).

Conditions

Interventions

DRUG

Pramipexole Oral Tablet

Pramipexole is an oral Dopamine agonist.

Sponsors & Collaborators

Principal Investigators

  • Leanne M Williams, PhD · Stanford University

Eligibility

Min Age
18 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2013-08-11
Primary Completion
2024-12-18
Completion
2025-04-02
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02220309 on ClinicalTrials.gov